Efficacy and immune mechanism of QingfeiTongluo prescriptions intervention on Mycoplasma pneumoniae pneumonia in children

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR1900002750

Enrollment

Unknown

Registered

2019-11-13

Start date

2019-11-15

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mycoplasma pneumoniae pneumonia

Interventions

experimental group:Qingfei Tongluo prescription combined with basic treatment

control group:Basic treatment

Eligibility

Sex/Gender

All

Age

6 Years to 16 Years

Inclusion criteria

Inclusion criteria: 1. Patients with Mycoplasma pneumoniae pneumonia or refractory Mycoplasma pneumoniae pneumonia; 2. Aged 6-16 years; 3. Parents signed informed consent.

Exclusion criteria

Exclusion criteria: 1. With severe active infection or serious heart, liver, kidney and hematopoietic system diseases, or other basic diseases. 2. The withdrawal time of other clinical trial drugs is less than 4 weeks.

Design outcomes

Primary

Measure	Time frame
curative effect;	—

Countries

China

Contacts

Public ContactZhao Jiuling

jiuling999@163.com+86 022-27435143

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026